JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Prognostic utility of biopsy-based PTEN and ERG status on biochemical progression and overall survival after SBRT for localized prostate cancer

  • 0Department of Radiation Oncology, University of North Carolina (UNC) School of Medicine, Chapel Hill, NC, United States.
Frontiers in Oncology +

|

April 8, 2024

|

April 8, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Genetic abnormalities like PTEN deletions and ERG rearrangements in prostate cancer patients treated with SBRT are linked to worse outcomes. Identifying these biomarkers on biopsy can help predict treatment success and inform future trials.

Area Of Science

  • Oncology
  • Genetics
  • Radiation Oncology

Background

  • Phosphatase and tensin homolog (PTEN) deletions and TMPRSS2-ERG rearrangements are common genetic alterations in prostate cancer.
  • These genetic abnormalities are associated with poorer clinical outcomes in prostate cancer patients.
  • Stereotactic Body Radiation Therapy (SBRT) is a treatment modality for localized prostate cancer.

Purpose Of The Study

  • To evaluate the impact of biopsy-determined PTEN losses and TMPRSS2-ERG fusion on outcomes in prostate cancer patients treated with SBRT.
  • To assess the effect of these genetic alterations on biochemical progression-free survival (bPFS) and overall survival (OS).

Main Methods

  • Prospective study of localized prostate cancer patients receiving SBRT.
  • Biopsy cores were analyzed for PTEN and ERG abnormalities.
  • Kaplan-Meier and Cox proportional hazards methods were used to analyze bPFS and OS.

Main Results

  • Wild-type ERG status was associated with significantly improved 5-year bPFS (94.1% vs. 72.4%).
  • Absence of PTEN alterations significantly improved 5-year bPFS (91.0% vs. 67.9%) and OS (96.4% vs. 79.4%).
  • Combined analysis showed significant differences in bPFS and OS based on ERG and PTEN status, with the ERG+/PTEN+ phenotype having the best outcomes.

Conclusions

  • Biopsy-detected ERG rearrangements and PTEN deletions correlate with poorer oncologic outcomes in prostate cancer patients undergoing SBRT.
  • These genetic markers are valuable for predicting treatment response and survival.
  • Further prospective studies are warranted to validate these findings.

Keywords: